{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:14:35Z","timestamp":1790810075463,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","award":["00149014\/WB-2023-50799"],"award-info":[{"award-number":["00149014\/WB-2023-50799"]}],"id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["101136464"],"award-info":[{"award-number":["101136464"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence nationale de la recherche","doi-asserted-by":"publisher","award":["ANR-24-EXME-0005 \\u2013 PEPR MEDOOC \\u2013 TME-on-Chip"],"award-info":[{"award-number":["ANR-24-EXME-0005 \\u2013 PEPR MEDOOC \\u2013 TME-on-Chip"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xcrm.2026.103011","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:10:32Z","timestamp":1787929832000},"page":"103011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor-on-chip as a personalized platform for rapid drug testing in breast cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"Clara","family":"Helal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8645-071X","authenticated-orcid":false,"given":"L\u00e9a","family":"Pinon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccolo","family":"Schintu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9na","family":"Domalain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Nurmik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9gol\u00e8ne","family":"Ladaigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Montaudon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sourd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heloise","family":"Derrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vincent-Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toulsie","family":"Ramtohul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Marangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7082-9792","authenticated-orcid":false,"given":"Maria Carla","family":"Parrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5515-9180","authenticated-orcid":false,"given":"Luc","family":"Cabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0027-352X","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Descroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103011_bib1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.103011_bib2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global Patterns and Trends in Breast Cancer Incidence and Mortality Across 185 Countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103011_bib3","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103011_bib4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.24.00248","article-title":"Endocrine and Targeted Therapy for Hormone Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer\u2014Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update","volume":"42","author":"Burstein","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103011_bib5","article-title":"Emerging Treatments in HER2-Positive Advanced Breast Cancer: Keep Raising the Bar","volume":"5","author":"Agostinetto","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.103011_bib6","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular Alterations in Triple-Negative Breast Cancer\u2014the Road to New Treatment Strategies","volume":"389","author":"Denkert","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.103011_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071102","article-title":"Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies","volume":"17","author":"Carvalho","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2026.103011_bib8","first-page":"6","article-title":"Chemotherapy Treatment Considerations in Metastatic Breast Cancer","volume":"12","author":"Hanna","year":"2021","journal-title":"JADPRO"},{"key":"10.1016\/j.xcrm.2026.103011_bib9","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly Targeted Therapy Based on Tumour Molecular Profiling Versus Conventional Therapy for Advanced Cancer (SHIVA): A Multicentre, Open-Label, Proof-of-Concept, Randomised, Controlled Phase 2 Trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.103011_bib10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.103011_bib11","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular Profiling of Cancer Patients Enables Personalized Combination Therapy: The i-PREDICT Study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103011_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202101176","article-title":"Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer","volume":"8","author":"Chen","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xcrm.2026.103011_bib13","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1078-0432.CCR-22-3334","article-title":"National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103011_bib14","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41588-024-01785-9","article-title":"Analysis of 10,478 Cancer Genomes Identifies Candidate Driver Genes and Opportunities for Precision Oncology","volume":"56","author":"Kinnersley","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2026.103011_bib15","first-page":"322","article-title":"The Treatment of Breast Cancer in the Era of Precision Medicine","volume":"22","author":"Bai","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.xcrm.2026.103011_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14060561","article-title":"Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine","volume":"14","author":"Masucci","year":"2024","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.xcrm.2026.103011_bib17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12967-022-03405-8","article-title":"Patient-Derived Xenograft (PDX) Models, Applications and Challenges in Cancer Research","volume":"20","author":"Abdolahi","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103011_bib18","doi-asserted-by":"crossref","first-page":"1350935","DOI":"10.3389\/fonc.2024.1350935","article-title":"Patient-Derived Organoids: A Promising Tool for Breast Cancer Research","volume":"14","author":"Shi","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.103011_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional Precision Oncology: Testing Tumors with Drugs to Identify Vulnerabilities and Novel Combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.103011_bib20","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/nm.2454","article-title":"Tumor Grafts Derived from Women with Breast Cancer Authentically Reflect Tumor Pathology, Growth, Metastasis and Disease Outcomes","volume":"17","author":"DeRose","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103011_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-Derived Xenograft Models in Cancer Therapy: Technologies and Applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2026.103011_bib22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-011-1815-5","article-title":"Modeling of Response to Endocrine Therapy in a Panel of Human Luminal Breast Cancer Xenografts","volume":"133","author":"Cottu","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2026.103011_bib23","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-07-0078","article-title":"A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays","volume":"13","author":"Marangoni","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103011_bib24","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-12-4081","article-title":"A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models","volume":"73","author":"Zhang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103011_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10549-012-2164-8","article-title":"Patient-Derived Luminal Breast Cancer Xenografts Retain Hormone Receptor Heterogeneity and Help Define Unique Estrogen-Dependent Gene Signatures","volume":"135","author":"Kabos","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.xcrm.2026.103011_bib26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","article-title":"Patient-Derived Organoids in Precision Cancer Medicine","volume":"5","author":"Tong","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.xcrm.2026.103011_bib27","article-title":"Multifocal Organoid Capturing of Colon Cancer Reveals Pervasive Intratumoral Heterogenous Drug Responses","volume":"9","author":"Kim","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xcrm.2026.103011_bib28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13046-023-02853-4","article-title":"Implementing Patient Derived Organoids in Functional Precision Medicine for Patients with Advanced Colorectal Cancer","volume":"42","author":"Cartry","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103011_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41698-021-00168-1","article-title":"Patient-Derived Organoids as a Predictive Biomarker for Treatment Response in Cancer Patients","volume":"5","author":"Wensink","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.xcrm.2026.103011_bib30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/j.gastro.2024.05.032","article-title":"Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer","volume":"167","author":"Boil\u00e8ve","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xcrm.2026.103011_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.103011_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102226","article-title":"Patient-Derived Tumor Organoids: A Preclinical Platform for Personalized Cancer Therapy","volume":"51","author":"Taurin","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.xcrm.2026.103011_bib33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s43018-020-0102-y","article-title":"Applications of Organoids for Cancer Biology and Precision Medicine","volume":"1","author":"Lo","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.103011_bib34","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1039\/D3LC00531C","article-title":"Bridging the Gap Between Tumor-on-Chip and Clinics: A Systematic Review of 15 Years of Studies","volume":"23","author":"Bouquerel","year":"2023","journal-title":"Lab Chip"},{"key":"10.1016\/j.xcrm.2026.103011_bib35","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2017.0137","article-title":"Tumour-on-a-Chip: Microfluidic Models of Tumour Morphology, Growth and Microenvironment","volume":"14","author":"Tsai","year":"2017","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.xcrm.2026.103011_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12195-022-00755-7","article-title":"The Applications and Challenges of the Development of in Vitro Tumor Microenvironment Chips","volume":"16","author":"Johnson","year":"2023","journal-title":"Cell. Mol. Bioeng."},{"key":"10.1016\/j.xcrm.2026.103011_bib37","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1016\/j.celrep.2018.12.015","article-title":"Dissecting Effects of Anti-Cancer Drugs and Cancer-Associated Fibroblasts by on-Chip Reconstitution of Immunocompetent Tumor Microenvironments","volume":"25","author":"Nguyen","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.103011_bib38","article-title":"Assessing Personalized Responses to Anti-PD-1 Treatment Using Patient-Derived Lung Tumor-on-Chip","volume":"5","author":"Veith","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.103011_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2025.103895","article-title":"Protocol for the Biofabrication of Immunocompetent Tumor-on-Chip Models from Patient Solid Tumors for Assessment of Anticancer Therapies","volume":"6","author":"Nurmik","year":"2025","journal-title":"STAR Protoc."},{"key":"10.1016\/j.xcrm.2026.103011_bib40","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1039\/D0LC00801J","article-title":"Microdissected \u2018Cuboids\u2019 for Microfluidic Drug Testing of Intact Tissues","volume":"21","author":"Horowitz","year":"2021","journal-title":"Lab Chip"},{"key":"10.1016\/j.xcrm.2026.103011_bib41","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/0008-5472.CAN-21-0799","article-title":"A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture","volume":"82","author":"Chakrabarty","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103011_bib42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41523-023-00583-6","article-title":"Proof-of-Concept Study Linking Ex Vivo Sensitivity Testing to Neoadjuvant Anthracycline-Based Chemotherapy Response in Breast Cancer Patients","volume":"9","author":"Ladan","year":"2023","journal-title":"Npj Breast Cancer"},{"key":"10.1016\/j.xcrm.2026.103011_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.952726","article-title":"A Comparative Study of Tumour-on-Chip Models with Patient-Derived Xenografts for Predicting Chemotherapy Efficacy in Colorectal Cancer Patients","volume":"10","author":"Ong","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103011_bib44","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s42003-023-05531-5","article-title":"A Fully 3D-Printed Versatile Tumor-on-a-Chip Allows Multi-Drug Screening and Correlation with Clinical Outcomes for Personalized Medicine","volume":"6","author":"Steinberg","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xcrm.2026.103011_bib45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40164-025-00647-2","article-title":"Extracellular Matrix Stiffness: Mechanisms in Tumor Progression and Therapeutic Potential in Cancer","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.103011_bib46","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1172\/JCI129249","article-title":"Stiff Stroma Increases Breast Cancer Risk by Inducing the Oncogene ZNF217","volume":"130","author":"Northey","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.103011_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0159013","article-title":"Co-Culture of Tumor Spheroids and Fibroblasts in a Collagen Matrix-Incorporated Microfluidic Chip Mimics Reciprocal Activation in Solid Tumor Microenvironment","volume":"11","author":"Jeong","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.103011_bib48","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1021\/acs.biomac.3c00257","article-title":"Collagen-Laponite Nanoclay Hydrogels for Tumor Spheroid Growth","volume":"24","author":"Alam\u00e1n-D\u00edez","year":"2023","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.xcrm.2026.103011_bib49","article-title":"Cholangiocarcinoma-on-a-Chip: A Human 3D Platform for Personalised Medicine","volume":"6","author":"Polidoro","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.xcrm.2026.103011_bib50","doi-asserted-by":"crossref","first-page":"5169","DOI":"10.1021\/acs.biomac.4c00551","article-title":"Polydopamine Interfacial Coating for Stable Tumor-on-a-Chip Models: Application for Pancreatic Ductal Adenocarcinoma","volume":"25","author":"Hern\u00e1ndez-Hatibi","year":"2024","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.xcrm.2026.103011_bib51","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1535-7163.MCT-23-0471","article-title":"Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations","volume":"23","author":"Meric-Bernstam","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2026.103011_bib52","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.annonc.2025.07.017","article-title":"Updated Treatment Recommendations for Systemic Treatment: From the ESMO Metastatic Breast Cancer Living Guideline","volume":"36","author":"Trapani","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.103011_bib53","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103011_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/antib10040042","article-title":"Introduction to Antibody-Drug Conjugates","volume":"10","author":"Pettinato","year":"2021","journal-title":"Antibodies"},{"key":"10.1016\/j.xcrm.2026.103011_bib55","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1158\/1078-0432.CCR-21-1560","article-title":"Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors","volume":"27","author":"Takahashi","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103011_bib56","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cpt.2096","article-title":"Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients with HER2-Positive Breast Cancer and Other Solid Tumors","volume":"109","author":"Yin","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2026.103011_bib57","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/psp4.13133","article-title":"Quantitative Evaluation of Trastuzumab Deruxtecan Pharmacokinetics and Pharmacodynamics in Mouse Models of Varying Degrees of HER2 Expression","volume":"13","author":"Vasalou","year":"2024","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.103011_bib58","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103011_bib59","first-page":"263","article-title":"Patient-Derived Organoids (PDOs) and PDO-Derived Xenografts (PDOXs): New Opportunities in Establishing Faithful Pre-Clinical Cancer Models","volume":"2","author":"Wang","year":"2022","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.xcrm.2026.103011_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab Deruxtecan in Breast Cancer","volume":"198","author":"Mart\u00edn","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.xcrm.2026.103011_bib61","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective Extracellular Payload Release and Immunomodulatory Interactions Govern the Therapeutic Effect of Trastuzumab Deruxtecan (t-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103011_bib62","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander Killing Effect of DS-8201a, a Novel Anti-Human Epidermal Growth Factor Receptor 2 Antibody\u2013Drug Conjugate, in Tumors with Human Epidermal Growth Factor Receptor 2 Heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.xcrm.2026.103011_bib63","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/0008-5472.CAN-25-0966","article-title":"An Extracellular Matrix\u2013Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation","volume":"86","author":"Hofer","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103011_bib64","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/path.5698","article-title":"Prostate Cancer Patient-Derived Organoids: Detailed Outcome from a Prospective Cohort of 81 Clinical Specimens","volume":"254","author":"Servant","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.xcrm.2026.103011_bib65","series-title":"R: A Language and Environment for Statistical Computing","year":"2021"},{"key":"10.1016\/j.xcrm.2026.103011_bib66","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: An Open-Source Platform for Biological-Image Analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2026.103011_bib67","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1158\/1078-0432.CCR-17-3490","article-title":"Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers","volume":"24","author":"Marangoni","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103011_bib68","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41467-023-37537-2","article-title":"Homologous Recombination Deficiency Derived from Whole-Genome Sequencing Predicts Platinum Response in Triple-Negative Breast Cancers","volume":"14","author":"Ter Brugge","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103011_bib69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-020-0846-y","article-title":"Combination of PI3K and MEK Inhibitors Yields Durable Remission in PDX Models of PIK3CA-Mutated Metaplastic Breast Cancers","volume":"13","author":"Coussy","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.103011_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2625","article-title":"BRCAness, SLFN11, and RB1 Loss Predict Response to Topoisomerase i Inhibitors in Triple-Negative Breast Cancers","volume":"12","author":"Coussy","year":"2020","journal-title":"Sci. Transl. Med."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:45:45Z","timestamp":1789591545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126004283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666379126004283"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103011","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-on-chip as a personalized platform for rapid drug testing in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103011"}}